Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol.
about
Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.Short-term aluminum administration in the rat. Effects on bone formation and relationship to renal osteomalacia.Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Failure to heal D-deficiency rickets and suppress secondary hyperparathyroidism with conventional doses of 1,25-dihydroxy vitamin D3.Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferolHistomorphometric evaluation of the effects of intermittent 1,25-dihydroxycholecalciferol administration on cortical bone remodeling in adult dogs.Light- and electron-microscopic evaluation of the effects of 1,25-dihydroxyvitamin D3 on bone of thyroparathyroidectomized rats.Regulation of secretion of parathormone and secretory protein-I from separate intracellular pools by calcium, dibutyryl cyclic AMP, and (1)-isoproterenol.Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands.Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells.Animal models of hyperfunctioning parathyroid diseases for drug development.The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOSalmon calcitonin-induced stimulation of 1 alpha,25-dihydroxycholecalciferol synthesis in rats involving a mechanism independent of adenosine 3':5'-cyclic monophosphate.Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calciumStimulation of bone formation and bone resorption by fluoride in thyroparathyroidectomized rats.The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.Calcium and phosphorus deficiency in rats: effects on PTH and 1,25-dihydroxyvitamin D3.Rationale for active vitamin D analog therapy in senile osteoporosis.Parathyroid hormone release is not associated with acute sympathetic arousal in goats.Effects of vitamin D metabolites on bovine parathyroid hormone release in vitro.Arterial calcifications in uraemic rats treated with 1-alpha-hydroxycholecalciferol and parathyroidectomy.Effects of vitamin D
P2860
Q34543837-1A556505-004E-414E-9816-A2206612AADBQ34599720-9AA91890-BF18-4B6B-864D-B7FF8239340BQ34622644-8B283F20-9467-4C20-9F7E-1347D1157652Q34749171-CF11070A-2FAF-49A4-8508-9233EFFD0B71Q34985753-B9AF6683-A047-4724-A1A8-442A37271C58Q35863867-3D1D23C3-0CA7-44C8-B855-1B341EEB3710Q36093281-D57D8036-4885-4625-97D5-27F1E7F4BBEEQ36200657-F6592A90-FCBD-445D-AC0B-B050B30A4272Q37000238-10F5DDF0-4D8D-480B-B658-4EFFDFD0B049Q37045927-BF318411-80FE-4E20-887F-B575E4446AB3Q37053921-B8AB5CA2-1A1F-49DD-B04C-8D52412AAAA9Q37464337-FD3163B5-7381-45B3-A9A7-9AC450845245Q37692403-E4C10D35-016C-496F-B55C-25F731A64BCFQ38089204-4FB93CC1-678F-47C8-8626-D0E02B5F5A9FQ38452740-C3F1D73E-320E-4F16-949B-BA9216EEC010Q40284622-E2D9AC01-E71C-4BA2-836C-9AC189536EC9Q40379315-71DF2214-C52E-467F-BFBE-8DE5DB1FE45AQ40482311-62F9BE92-F203-4315-879E-EA0FB0086C2FQ40511401-4F1793FD-D799-486A-AEE0-0018AF7D579FQ40919559-5C4856F8-5AF0-4201-87C0-145CBA4DE5F9Q41436004-9BA05F15-DD0E-4D80-85C3-7AF2596DAAC8Q46601219-040BB147-2001-4B4A-9842-B379351809A1Q48121590-515B22FF-52A1-494B-AD07-FC331C2564C3Q54359102-2A606130-BA43-4120-9234-031E87CDD53DQ54584892-3865B587-A724-4F9C-85CE-7055F47AD607Q58077248-BD06AA96-6E1F-4CEA-A7B8-B029ED6F3D0E
P2860
Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol.
description
1975 nî lūn-bûn
@nan
1975 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@ast
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@en
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@nl
type
label
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@ast
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@en
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@nl
prefLabel
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@ast
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@en
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@nl
P2093
P2860
P356
P1476
Decrease in serum immunoreacti ...... 1,25-dihydroxycholecalciferol.
@en
P2093
P2860
P304
P356
10.1172/JCI108137
P407
P577
1975-09-01T00:00:00Z